13F-HR filed by Flagship Pioneering, LLC
Flagship Pioneering, LLC filed this 13F-HR for the quarter ended 2018-09-30, filed 2018-11-13, with 6 holding rows worth $1,513,015,000.
- Accession
- 0001012975-18-001201
- Filer
- CIK 1400240
- Filed
- 2018-11-13
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2018
A holdings report, 10 entries on the cover page, a total value of $1,513,015,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,513,015,000 with VALUE read as thousands by filing date, 13F file number 028-17559. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerFlagship Ventures Fund V General Partner LLC028-18466
- included managerFlagship Ventures Fund IV General Partner LLC028-17238
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| RUBIUS THERAPEUTICS INC | 78116T103 | COM | 38,296,526 | $919,117,000 | thousands by filing date | |
| EVELO BIOSCIENCES INC | 299734103 | COM | 18,233,403 | $222,083,000 | thousands by filing date | |
| DENALI THERAPEUTICS INC COM | 24823R105 | Stock | 8,918,749 | $193,894,000 | thousands by filing date | |
| SERES THERAPEUTICS INC | 81750R102 | COM | 12,682,876 | $96,263,000 | thousands by filing date | |
| QUANTERIX CORP | 74766Q101 | COMMON STOCK | 2,030,495 | $43,493,000 | thousands by filing date | |
| SYROS PHARMACEUTICALS INC | 87184Q107 | COM | 3,204,437 | $38,165,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001012975-18-001201 | this filing | 2018-11-13 | acceptance time not in the bulk data set |